Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia

Cancer

Volumn 121, Issue 21, 2015, Pages 3869-3876

  Short, Nicholas J ^a   Keating, Michael J ^a   Wierda, William G ^a   Faderl, Stefan ^b   Ferrajoli, Alessandra ^a   Estrov, Zeev ^a   Smith, Susan C ^a   O'Brien, Susan M ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

and rituximab (FCR); chemoimmunotherapy; chronic lymphocytic leukemia; cyclophosphamide; fludarabine; rituximab; therapy related acute myelogenous leukemia; therapy related myelodysplastic syndrome

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; VIDARABINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER INCIDENCE; CANCER REGRESSION; CANCER SURVIVAL; CELLULITIS; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOPENIA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PENIS CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RICHTER SYNDROME; SEPTICEMIA; SINUSITIS; SPLENOMEGALY; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; FOLLOW UP; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; RITUXIMAB; SURVIVAL RATE; TREATMENT OUTCOME; VIDARABINE;

EID: 84945489166     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29605     Document Type: Article

References (29)

1. Eichhorst BF, Busch R, Hopfinger G, et al., Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107: 885-891.
2. Flinn IW, Neuberg DS, Grever MR, et al., Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007; 25: 793-798.
3. Catovsky D, Richards S, Matutes E, et al., Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007; 370: 230-239.
4. Keating MJ, O'Brien S, Albitar M, et al., Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4079-4088.
5. Tam CS, O'Brien S, Wierda W, et al., Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980.
6. Hallek M, Fischer K, Fingerle-Rowson G, et al., Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.
7. Hainsworth JD, Litchy S, Barton JH, et al., Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003; 21: 1746-1751.
8. McLaughlin P, Grillo-Lopez AJ, Link BK, et al., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 2825-2833.
9. Huhn D, von Schilling C, Wilhelm M, et al., Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001; 98: 1326-1331.
10. Almasri NM, Duque RE, Iturraspe J, Everett E, Braylan RC,. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol. 1992; 40: 259-263.
11. Byrd JC, Murphy T, Howard RS, et al., Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001; 19: 2153-2164.
12. O'Brien SM, Kantarjian H, Thomas DA, et al., Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001; 19: 2165-2170.
13. Cheson BD, Bennett JM, Grever M, et al., National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
14. Rawstron AC, Villamor N, Ritgen M, et al., International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007; 21: 956-964.
15. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
16. National Comprehensive Cancer Network. Non-Hodgkin's lymphomas (version 5.2014). http://www.nccn.org/professionals/physician-gls/pdf/nhl.pdf. Accessed December 1, 2014.
17. Bottcher S, Ritgen M, Fischer K, et al., Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30: 980-988.
18. Strati P, Keating MJ, O'Brien SM, et al., Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014; 123: 3727-3732.
19. Alas S, Bonavida B, Emmanouilides C,. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res. 2000; 20: 2961-2966.
20. Chow KU, Sommerlad WD, Boehrer S, et al., Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica. 2002; 87: 33-43.
21. Di Gaetano N, Xiao Y, Erba E, et al., Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001; 114: 800-809.
22. Zhou Y, Tang G, Medeiros LJ, et al., Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012; 25: 237-245.
23. Fischer K, Bahlo J, Fink AM, et al., Extended follow up of the CLL8 protocol, a randomized phase-III trial of the German CLL Study Group (GCLLSG) comparing fludarabine and cyclophosphamide (FC) to FC plus rituximab (FCR) for previously untreated patients with chronic lymphocytic leukemia (CLL): results on survival, progression-free survival, delayed neutropenias and secondary malignancies confirm superiority of the FCR regimen. Poster presented at: 54th ASH Annual Meeting and Exposition; December 8-11, 2012; Atlanta, GA.
24. Abrisqueta P, Villamor N, Terol MJ, et al., Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood. 2013; 122: 3951-3959.
25. Tarella C, Passera R, Magni M, et al., Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma. J Clin Oncol. 2011; 29: 814-824.
26. Greil R, Obrtlikova P, Smolej L, et al., Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a maintenance trial. Poster presented at: 56th ASH Annual Meeting and Exposition; December 6-9, 2014; San Francisco, CA.
27. Li Q, Teitz-Tennenbaum S, Donald EJ, Li M, Chang AE,. In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. J Immunol. 2009; 183: 3195-3203.
28. Li Q, Lao X, Pan Q, et al., Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res. 2011; 17: 4987-4995.
29. Strati P, Ferrajoli A, Lerner S, et al., Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2014; 55: 828-833.